



DIVISION OF  
CORPORATION FINANCE

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

February 26, 2019

Raymond Urbanski, M.D., Ph.D.  
Chief Executive Officer and Chairman of the Board  
GT Biopharma, Inc.  
310 N. Westlake Blvd  
Suite 206  
Westlake Village, CA 91362

**Re: GT Biopharma, Inc.**  
**Registration Statement on Form S-3**  
**Filed February 14, 2019**  
**File No. 333-229667**

Dear Dr. Urbanski:

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Jeffrey Gabor at 202-551-2544 with any questions.

Sincerely,

Division of Corporation Finance  
Office of Healthcare & Insurance

cc: Gary R. Henrie, Esq.